BioPharma Resources

Drug Trial Radar · NCT03597516

Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance

Last checked: Nov 19, 2026Latest source record: Jul 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 557 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

557

Actual

Start

Jun 26, 2018

Primary completion

Jul 2, 2019

Study completion Jul 2, 2019

Sponsor

Lead sponsor
Ritter Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.

Conditions

  • Lactose Intolerance

Interventions

  • RP-G28Drug

    powder for reconstitution for oral administration

  • PlacebosDrug

    powder for reconstitution for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline of the Lactose Intolerance (LI) symptom composite score compared to placeboTime frame: Day 61

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Research Facility

    Birmingham, Alabama

  • Research Site

    Chula Vista, California

  • Research Site

    Huntington Park, California

  • Research Site

    Lincoln, California

  • Research Site

    Los Angeles, California

  • Research Site

    Panorama City, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Gainesville, Florida

  • Research Facility

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Reseaarch Site

    Pompano Beach, Florida

  • Research Site

    Honolulu, Hawaii

  • Research Site

    Marrero, Louisiana

  • Research Site

    Oxon Hill, Maryland

  • Research Site

    Wyoming, Michigan

  • Research Site

    Omaha, Nebraska

  • Research Site

    Berlin, New Jersey

  • Research Site

    Albuquerque, New Mexico

  • Research Site

    Brooklyn, New York

  • Research Site

    Great Neck, New York

  • Research Site

    Hartsdale, New York

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Dayton, Ohio

  • Research Site

    Charleston, South Carolina

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Lampasas, Texas

  • Research Site

    San Antonio, Texas

  • Research Site

    Waxahachie, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.